HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target

Inovio Pharmaceuticals (NASDAQ:INO) has been given a $13.00 price objective by investment analysts at HC Wainwright in a research report issued on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 180.17% from the company’s current price.

Several other equities analysts also recently commented on INO. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. Royal Bank of Canada assumed coverage on Inovio Pharmaceuticals in a report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target on the stock. ValuEngine downgraded Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, November 9th. Citigroup assumed coverage on Inovio Pharmaceuticals in a report on Friday, October 6th. They set a “buy” rating and a $10.00 price target on the stock. Finally, BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. Inovio Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $19.16.

Inovio Pharmaceuticals (NASDAQ INO) opened at $4.64 on Tuesday. Inovio Pharmaceuticals has a twelve month low of $4.09 and a twelve month high of $9.86. The company has a market capitalization of $418.97, a P/E ratio of -3.93 and a beta of 2.74.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm had revenue of $2.60 million during the quarter, compared to analyst estimates of $10.27 million. During the same quarter in the prior year, the company posted ($0.28) EPS. The company’s quarterly revenue was down 79.2% on a year-over-year basis. equities research analysts forecast that Inovio Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 4.2% in the second quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock valued at $25,301,000 after acquiring an additional 129,164 shares during the period. BlackRock Fund Advisors boosted its position in shares of Inovio Pharmaceuticals by 1.4% in the first quarter. BlackRock Fund Advisors now owns 2,804,668 shares of the biopharmaceutical company’s stock valued at $24,429,000 after acquiring an additional 37,732 shares during the period. Wasatch Advisors Inc. boosted its position in shares of Inovio Pharmaceuticals by 3.1% in the third quarter. Wasatch Advisors Inc. now owns 2,691,331 shares of the biopharmaceutical company’s stock valued at $17,063,000 after acquiring an additional 80,513 shares during the period. Northern Trust Corp boosted its position in shares of Inovio Pharmaceuticals by 2.8% in the second quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock valued at $7,028,000 after acquiring an additional 24,366 shares during the period. Finally, Morgan Stanley boosted its position in shares of Inovio Pharmaceuticals by 10.5% in the fourth quarter. Morgan Stanley now owns 825,975 shares of the biopharmaceutical company’s stock valued at $5,551,000 after acquiring an additional 78,515 shares during the period. 32.11% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/23/hc-wainwright-analysts-give-inovio-pharmaceuticals-ino-a-13-00-price-target-2.html.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply